Literature DB >> 17571458

Tuberculosis vaccines - an update.

Peter Andersen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17571458     DOI: 10.1038/nrmicro1703

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


× No keyword cloud information.
  40 in total

1.  Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease.

Authors:  Lerisa Govender; Brian Abel; E Jane Hughes; Thomas J Scriba; Benjamin M N Kagina; Marwou de Kock; Gerhard Walzl; Gillian Black; Ida Rosenkrands; Gregory D Hussey; Hassan Mahomed; Peter Andersen; Willem A Hanekom
Journal:  Vaccine       Date:  2010-10-23       Impact factor: 3.641

Review 2.  Pneumonia research to reduce childhood mortality in the developing world.

Authors:  J Anthony G Scott; W Abdullah Brooks; J S Malik Peiris; Douglas Holtzman; E Kim Mulholland
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

3.  Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency.

Authors:  K F Siddiqui; M Amir; N Khan; G Rama Krishna; J A Sheikh; K Rajagopal; J N Agrewala
Journal:  Clin Exp Immunol       Date:  2015-06-03       Impact factor: 4.330

4.  Early secreted antigenic target of 6-kDa protein of Mycobacterium tuberculosis primes dendritic cells to stimulate Th17 and inhibit Th1 immune responses.

Authors:  Xisheng Wang; Peter F Barnes; Fangfang Huang; Ivana B Alvarez; Pierre F Neuenschwander; David R Sherman; Buka Samten
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

5.  Mycobacterium tuberculosis-specific CD8+ T cells require perforin to kill target cells and provide protection in vivo.

Authors:  Joshua S Woodworth; Ying Wu; Samuel M Behar
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

6.  Expression and immunogenicity of the mycobacterial Ag85B/ESAT-6 antigens produced in transgenic plants by elastin-like peptide fusion strategy.

Authors:  Doreen Manuela Floss; Michael Mockey; Galliano Zanello; Damien Brosson; Marie Diogon; Roger Frutos; Timothée Bruel; Valérie Rodrigues; Edwin Garzon; Claire Chevaleyre; Mustapha Berri; Henri Salmon; Udo Conrad; Laurence Dedieu
Journal:  J Biomed Biotechnol       Date:  2010-04-13

7.  Helminth coinfection does not affect therapeutic effect of a DNA vaccine in mice harboring tuberculosis.

Authors:  Fabiani G Frantz; Rogério S Rosada; Camila Peres-Buzalaf; Franciele R T Perusso; Vanderlei Rodrigues; Simone G Ramos; Steven L Kunkel; Célio L Silva; Lúcia H Faccioli
Journal:  PLoS Negl Trop Dis       Date:  2010-06-08

8.  Assessment of the genetic diversity of Mycobacterium tuberculosis esxA, esxH, and fbpB genes among clinical isolates and its implication for the future immunization by new tuberculosis subunit vaccines Ag85B-ESAT-6 and Ag85B-TB10.4.

Authors:  Jose Davila; Lixin Zhang; Carl F Marrs; Riza Durmaz; Zhenhua Yang
Journal:  J Biomed Biotechnol       Date:  2010-06-21

9.  Using epitope predictions to evaluate efficacy and population coverage of the Mtb72f vaccine for tuberculosis.

Authors:  Lucy A McNamara; Yongqun He; Zhenhua Yang
Journal:  BMC Immunol       Date:  2010-03-30       Impact factor: 3.615

10.  Immunological memory transferred with CD4 T cells specific for tuberculosis antigens Ag85B-TB10.4: persisting antigen enhances protection.

Authors:  Darragh Duffy; Amina Dawoodji; Else Marie Agger; Peter Andersen; Jürgen Westermann; Eric B Bell
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.